LivaNova PLC (NASDAQ:LIVN) has been given an average rating of “Buy” by the nine research firms that are presently covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $118.20.
LIVN has been the topic of a number of research analyst reports. Zacks Investment Research upgraded LivaNova from a “sell” rating to a “hold” rating in a report on Wednesday, July 4th. BidaskClub downgraded LivaNova from a “strong-buy” rating to a “buy” rating in a report on Thursday, July 12th. Needham & Company LLC reiterated a “buy” rating and set a $128.00 price target on shares of LivaNova in a report on Wednesday, July 18th. Stifel Nicolaus lifted their price target on LivaNova from $115.00 to $130.00 and gave the company a “buy” rating in a report on Tuesday, July 24th. Finally, Jefferies Financial Group lifted their price target on LivaNova to $150.00 and gave the company a “buy” rating in a report on Tuesday, October 2nd.
In other LivaNova news, insider David S. Wise sold 1,500 shares of the business’s stock in a transaction dated Monday, October 15th. The stock was sold at an average price of $112.83, for a total value of $169,245.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Daniel Jeffrey Moore sold 1,000 shares of the business’s stock in a transaction dated Monday, September 17th. The shares were sold at an average price of $123.49, for a total value of $123,490.00. The disclosure for this sale can be found here. Insiders sold 8,058 shares of company stock worth $963,033 in the last 90 days. Corporate insiders own 0.41% of the company’s stock.
Shares of NASDAQ LIVN remained flat at $$114.50 during mid-day trading on Tuesday. The company had a trading volume of 657,811 shares, compared to its average volume of 403,044. The company has a quick ratio of 1.08, a current ratio of 1.51 and a debt-to-equity ratio of 0.03. The firm has a market cap of $5.56 billion, a PE ratio of 33.19, a price-to-earnings-growth ratio of 3.35 and a beta of 0.95. LivaNova has a twelve month low of $72.30 and a twelve month high of $131.54.
LivaNova (NASDAQ:LIVN) last issued its earnings results on Wednesday, August 1st. The company reported $0.96 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.92 by $0.04. The business had revenue of $287.50 million for the quarter, compared to analysts’ expectations of $278.08 million. LivaNova had a positive return on equity of 9.24% and a negative net margin of 4.93%. The company’s quarterly revenue was up 12.4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.93 EPS. As a group, sell-side analysts expect that LivaNova will post 3.18 EPS for the current year.
LivaNova Company Profile
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves.
Featured Story: How to Invest in Marijuana Stocks
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.